The ComtecMed Medical Congresses is kindly inviting you to participate in the 1st Meeting of the Insulin Club – From Basic Science to Clinical Practise 2013, held October 31 – November 2, 2013 in Berlin, Germany at the Leonardo Royal Hotel.
The world-wide epidemics of obesity and secondarily type 2 diabetes, are well-known to all of us. While the increasing incidences of type 1 diabetes is perhaps less obvious, l it is indeed also occurring in many countries.
Basic and clinical research has intensified to try to understand the pathophysiology of these devastating disorders from genetics, to cell biology and to mouse models replicating the disorders. New medications are constantly being discovered, tested and introduced into clinical practice.
The “Insulin Club” has been created to bring together these concepts, to translate the latest research for those of us
involved in this area, thereby beginning a dialogue between the scientist and physician, with the realization that this interaction will benefit both the professionals as well as the patients.
Participants are provided ample opportunity to interact with world-renowned experts in these various fields, both researchers, clinical trialists and clinicians, with the aim of enabling clinicians to formulate and implement appropriate therapeutic approaches in their daily practices.
The “Insulin Club” meeting will present the latest research with an interactive platform for discussions between the attendees and the experts.
- Alternative route of insulin therapy
- Can GLP1 replace or postpone insulin therapy?
- Can new analogs replace pump therapy?
- Immunotherapy: Prior results, what worked, what has not
- Inflammation and islet dysfunction in obesity and T2D
- Insulin producing cells from different organs: liver, skin
- Insulin/GLP1 combination therapy-Can it replace the beta cell?
- Islet encapulation/Xenotransplantation
- Islet/Islet fate in T2D
- MIRNAs in insulin secretion and action
- Natural history of type 1 and type 2 diabetes
- Need for new analogs
- Place of CGM in type 1 and 2 diabetes
- Regulation of glucagon secretion in man
- Role of advanced glycation end products in the pathogenesis of type 1 or type 2 diabetes and their complications: Possible therapeutic interventions
- Role of incretin
- Role of insulin
- Role of PPAR gama
- Spontaneous transdifferentiation of alpha to beta cells
- Stem cell
- Subjective mechanisms in intake and a reproducible limit-hunger arousal and intake decisions before meals
- Transplantation of Pancreas/Islet transplant alone?
- Trialnet and future “proof of concept” studies
- G. Bolli, Italy
- W. Cefalu, USA
- S. Chera, Switzerland
- M. Ciampolini, Italy
- O. Cohen, Israel
- S. Del Prato, Italy
- M. Donath, Switzerland
- E. Gylfe, Sweden
- B. Hirshberg, USA
- P. Home, UK
- D. Leroith, USA
- I. Meivar-Levy, Israel
- A. Karasik, Israel
- M. Peppa, Greece
- P. Pozzilli, Italy
- I. Raz, Israel
- R. Regazzi, Switzerland
- R. Scharfmann, France
- E. Standl, Germany
- Participants who would like to actively participate in the Meeting, are requested to submit an abstract for review by the Scientific Committee.
- The Committee reserves the right to: 1) select the abstracts relevant to the sessions; 2) decide on the final form of presentation.
- The Committee will accept a maximum of 2 abstracts for presentation per presenting author.
Abstracts will be published on the Meeting website only on receipt of payment in full for registration.
Before you begin, please prepare the following information:
- Title of the abstract
- Family names and initials of all authors
- Details of affiliation of all author(s); institution, city, country
- Contact details of the presenting author (email, tel, fax)